clinical trial · NCT03411122
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers
Sumitomo Pharma America, Inc.·phase1·completed·n = 30
Drug-drug Interactionsnapabucasincytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
brief summary
This is a phase I, single-center, open-label, single-sequence, 3-period, PK drug interaction study evaluating the effect of napabucasin in healthy volunteers on the single-dose PK of several cytochrome P450 (CYP450) probe drugs as well as a BCRP substrate.
started
Jun 30, 2017
primary completion
Jan 23, 2018
completion
Jan 23, 2018
last updated
Nov 14, 2023
official title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol